Ohio is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
BHV-7000 Acute Treatment of Bipolar Mania
NCT06419582
Recruiting
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Midwest Clinical Research Center, Dayton, Ohio
Conditions: Bipolar Disorder
Register for Updates
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Centricity Research Columbus /ID# 257221, Columbus, Ohio
Conditions: Migraine
Register for Updates
Clareon PanOptix Pro vs. Clareon PanOptix - Study B
NCT06401551
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/18/2024
Locations: Cincinnati Eye Institute, Cincinnati, Ohio
Conditions: Aphakia, Presbyopia
Register for Updates
Clareon PanOptix Pro vs. Clareon PanOptix - Study A
NCT06400745
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/18/2024
Locations: Cincinnati Eye Institute, Cincinnati, Ohio
Conditions: Aphakia, Presbyopia
Register for Updates
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT06385080
Recruiting
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, and amivantamab in addition to paclitaxel in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Register for Updates
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy
NCT06378398
Recruiting
This trial will obtain biomarker data on the possible preventive effects of omeprazole and low-dose aspirin in colorectal tissue. Persons who have had 5 or more adenomas, 5 or more serrated polyps, or an incompletely removed adenoma or serrated polyp in the colon or rectum are potentially eligible. Before participating in the study, study staff will explain the study and review the consent form. If you are interested and provide consent, study staff will then confirm your eligibility. Once enrol... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Colorectal Neoplasia
Register for Updates
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339
Recruiting
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone [TSH]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Diabetes and Endocrinology Associates of Stark County Inc /ID# 256751, Canton, Ohio
Conditions: Hypothyroidism
Register for Updates
Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Reduction During Intrauterine Device (IUD) Insertion in Outpatient Gynecology
NCT06335823
Recruiting
Pain with intrauterine device (IUD) insertion is very common and there are few options for patients to help reduce this pain. Transcutaneous electric nerve stimulators (TENS) are a non-invasive procedure that may help reduce the pain with IUD insertions. The investigators hope that the information gleaned from this study will result in pain control options for future patients who desire an IUD placement.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
06/18/2024
Locations: University Hospitals, Cleveland, Ohio
Conditions: IUD Insertion Pain
Register for Updates
Preoperative (Pre-amputation) Cryoanalgesia to Improve Post-amputation Phantom Limb Pain
NCT06284109
Recruiting
Investigators will evaluate preamputation cryoanalgesia on pain, mobility, opioid use and general physical and emotional disability using a pilot randomized trial design, to explore the amount and variability of improvement on those outcomes and to investigate the potentiality of conducting a future larger randomized controlled trial, which the investigators will assess quantitatively the benefits of cryoanalgesia.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Postoperative Pain
Register for Updates
Promoting Caregiver Implementation of an Effective Early Learning Intervention
NCT06275815
Recruiting
The goal of this study is to examine the impact of a caregiver-implemented shared reading program, Sit Together and Read (STAR), on children ages 4 to 5 with developmental language disorder. The main questions it aims to answer are: how much STAR impacts children's literacy skills in the short-term and long-term--up to two-years after completing STAR. how do caregiver supports in the form of small monetary rewards or encouraging texts help caregivers to implement STAR at its intended frequency... Read More
Gender:
All
Ages:
Between 48 months and 71 months
Trial Updated:
06/18/2024
Locations: Schoenbaum Family Center; Crane Center for Early Childhood Research and Policy, Columbus, Ohio
Conditions: Developmental Language Disorder, Reading; Difficult
Register for Updates
SW-682 in Advanced Solid Tumors
NCT06251310
Recruiting
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) thera... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: SpringWorks Clinical Trial Site, Cleveland, Ohio
Conditions: Advanced Solid Tumor, Mesothelioma, Malignant
Register for Updates
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: The Urology Group, Cincinnati, Ohio
Conditions: Non-Muscle Invasive Bladder Neoplasms
Register for Updates